Comparison the Effect of Sitagliptin and Inositol on the Fertility Treatment in Polycystic Ovarian Syndrome

Phase 3

• Conditions: Polycystic Ovarian Syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT20240128060827N1
• Lead Sponsor: Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 70

Inclusion Criteria

People with Polycystic Ovarian Syndrome
Age Between 18 and 40 Years
People who are Known Case of Polycystic Ovarian Syndrome Based on Sonographic and Laboratory Findings Contained in the Case file
People who are Candidates for Infertility Treatment and ICSI Based on Infertility Records

Exclusion Criteria

People with Uterine Abnormalities (such as Asherman's Syndrome, Fibroids, Polyps, and a Diagnosis of Adenomyosis)
Contraindications for Inositol and Sitagliptin
Treatment Cycles with Embryo Donation or Prenatal Genetic Screening
Endometriosis and Infertility with Unknown Cause
Severe Male Factor Infertility

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oocyte Quality. Timepoint: 8 Weeks Later Use of Medications. Method of measurement: Microscope.;Embryo Quality. Timepoint: 8 Weeks Later Use of Medications. Method of measurement: Microscope.

Secondary Outcome Measures

Name	Time	Method
Body Mass Index. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Dividing Weight by Height to the Power of 2.;Luteinizing hormone. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.;Follicle stimulating hormone. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.;Fasting Blood Sugar. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.;Testosterone. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA test.